The company said, “As previously announced, Equillium (EQ) had no further intention to continue development of itolizumab, therefore on September 30, 2025, Biocon and Equillium entered into an agreement to terminate their collaboration and license agreement and other agreements relating to itolizumab.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EQ:
- Equillium Files Prospectus for $75 Million Stock Sale
- Equillium files to sell 52.63M shares of common stock for holders
- Equillium Regains Nasdaq Compliance with Bid Price Rule
- Equillium price target lowered to $4 from $8 at Jefferies
- Equillium’s Strategic Moves and Financial Position Lead to Hold Rating Amid Clinical Trial Uncertainties